Sundi D - Search Results

1

Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation.

Plote D, Choi W, Mokkapati S, Sundi D, Ferguson JE 3rd, Duplisea J, Parker NR, Yla-Herttuala S, Committee SCB, McConkey D, Schluns KS, Dinney CP. Plote D, et al. Among authors: sundi d. Oncoimmunology. 2019 Feb 20;8(5):e1577125. doi: 10.1080/2162402X.2019.1577125. eCollection 2019. Oncoimmunology. 2019. PMID: 31069136 Free PMC article.

2

Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.

Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah JB, Shrader M, Choi W, Lashinger LM, Chunduru S, McConkey DJ, McKinlay M, Kamat AM. Metwalli AR, et al. Among authors: sundi d. Cancer Biol Ther. 2010 Nov 1;10(9):885-92. doi: 10.4161/cbt.10.9.13237. Epub 2010 Nov 1. Cancer Biol Ther. 2010. PMID: 20814238 Free PMC article.

3

Upper tract urothelial carcinoma: impact of time to surgery.

Sundi D, Svatek RS, Margulis V, Wood CG, Matin SF, Dinney CP, Kamat AM. Sundi D, et al. Urol Oncol. 2012 May-Jun;30(3):266-72. doi: 10.1016/j.urolonc.2010.04.002. Epub 2010 Sep 25. Urol Oncol. 2012. PMID: 20869888 Free PMC article.

4

Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis.

Roth B, Jayaratna I, Sundi D, Cheng T, Melquist J, Choi W, Porten S, Nitti G, Navai N, Wszolek M, Guo C, Czerniak B, McConkey D, Dinney C. Roth B, et al. Among authors: sundi d. Oncotarget. 2017 May 23;8(21):34205-34222. doi: 10.18632/oncotarget.11009. Oncotarget. 2017. PMID: 27494900 Free PMC article.

5

Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection.

Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL. Svatek RS, et al. Among authors: sundi d. Cancer. 2009 Mar 15;115(6):1310-7. doi: 10.1002/cncr.24145. Cancer. 2009. PMID: 19156903 Free article.

6

Extent of pelvic lymph node dissection during radical cystectomy: is bigger better?

Sundi D, Svatek RS, Nielsen ME, Schoenberg MP, Bivalacqua TJ. Sundi D, et al. Rev Urol. 2014;16(4):159-66. Rev Urol. 2014. PMID: 25548542 Free PMC article. Review.

7

BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.

Kamat AM, Colombel M, Sundi D, Lamm D, Boehle A, Brausi M, Buckley R, Persad R, Palou J, Soloway M, Witjes JA. Kamat AM, et al. Among authors: sundi d. Nat Rev Urol. 2017 Apr;14(4):244-255. doi: 10.1038/nrurol.2017.16. Epub 2017 Feb 21. Nat Rev Urol. 2017. PMID: 28248951 Review.

8

Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?

Reichard CA, Nyame YA, Sundi D, Tosoian J, Wilkins L, Alam R, Achim MF, Wang X, Stephenson AJ, Klein EA, Ross AE, Davis JW, Chapin BF. Reichard CA, et al. Among authors: sundi d. BJU Int. 2019 Aug;124(2):282-289. doi: 10.1111/bju.14671. Epub 2019 Feb 10. BJU Int. 2019. PMID: 30653804

9

Very-high-risk (VHR) localized prostate cancer: an indication for multimodal therapy.

Sundi D, Chapin BF. Sundi D, et al. Oncotarget. 2019 Mar 8;10(20):1870-1871. doi: 10.18632/oncotarget.26757. eCollection 2019 Mar 8. Oncotarget. 2019. PMID: 30956769 Free PMC article. No abstract available.

10

Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.

Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM. Li R, et al. Among authors: sundi d. Eur Urol. 2020 Sep;78(3):387-399. doi: 10.1016/j.eururo.2020.02.012. Epub 2020 Mar 4. Eur Urol. 2020. PMID: 32143924 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

65 results

Search Page